Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
92.41
+20.14 (27.87%)
At close: Oct 30, 2025, 4:00 PM EDT
89.32
-3.09 (-3.34%)
Pre-market: Oct 31, 2025, 4:16 AM EDT
Guardant Health Employees
As of December 31, 2024, Guardant Health had 2,021 total employees, including 1,999 full-time and 22 part-time employees. The number of employees increased by 242 or 13.60% compared to the previous year.
Employees
2,021
Change (1Y)
242
Growth (1Y)
13.60%
Revenue / Employee
$446,595
Profits / Employee
-$197,323
Market Cap
11.65B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,021 | 242 | 13.60% |
| Dec 31, 2023 | 1,779 | -14 | -0.78% |
| Dec 31, 2022 | 1,793 | 420 | 30.59% |
| Dec 31, 2021 | 1,373 | 509 | 58.91% |
| Dec 31, 2020 | 864 | 242 | 38.91% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GH News
- 7 hours ago - Guardant Health: Business Continues To Gather Pace - Seeking Alpha
- 1 day ago - Guardant Health, Inc. (GH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - Business Wire
- 3 days ago - Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights - Business Wire
- 4 days ago - Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 - Business Wire
- 15 days ago - Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025 - Business Wire
- 21 days ago - Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 - Business Wire
- 4 weeks ago - FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer - Business Wire